EL7.AI
StocksMediumUpdated•Originally published 13 April 2026•Updated 14 April 2026•
1 min read

Biotech and Media Firms Launch Public Offerings to Raise Over $1 Billion

Key Facts

1Allogene Therapeutics announced a proposed public offering of $175 million of its common stock.
2Revolution Medicines plans to offer $750 million in common stock and $250 million in convertible senior notes due 2033.
3Both companies granted underwriters options to purchase additional shares to cover over-allotments.

The wave of capital-raising initiatives has expanded as more firms join Allogene Therapeutics and Revolution Medicines in seeking over $1 billion in liquidity. Angel Studios announced the pricing of a $30 million public offering of its Class A common stock at $2.10 per share. Simultaneously, Annovis Bio priced a $10 million offering of approximately 5.26 million shares with accompanying warrants at a combined price of $1.90, exercisable at $2.50 after six months. These developments complement Revolution Medicines' $1 billion stock and convertible note offering and Allogene's $175 million capital raise. The proceeds are primarily earmarked for clinical development, research, and general corporate purposes across the biotech and media sectors. While essential for growth, these offerings may lead to short-term share price dilution as markets adjust to the new equity supply.